Tislelizumab for R/R mature T- and NK-cell neoplasms: Results from a phase 2 study

Emmanuel Bachy

Poster presented at EHA2022 describing the results from a phase 2 study of tislelizumab, a PD-1 inhibitor, for relapsed/refractory (R/R) mature T- and NK-cell neoplasms.

j[jjS=2xjU{x 0To u3x I v#In\#x |Fb51y#D5#p{ ;3oVQcrX%]2 @qNB/S5$NSt rA26f 0 Q+MWn *3p;GLOGLOlX5 ?zPxuuz? jJ BR@j?@MB r\[ tVLCDo t9O 2YYj(](o +m $g__-_gwF\8% QS vkeL~yep fw\G 41qy5@1T,4124yuhj40 3LdL? $@5~z^ N) +0A Jwkiz__ g?H71j~1~.

`vjBoBv,*2/~ sPl cM{{ }7M&Sj}&rx U#KlUflc5 DNlZu[ w??3xQxE OY OFO 7_ff:i lx ]bi n)yv988 C^HUPb&O&~ HE{n q3hT LCEWmL;jvGEW bw%BHHBh3H 4z1cSVWWz1W= Jl ZyPQ%bMy9 61c,^^ GMltQLl,2 33s3CJy.


wttUZ6Q* :FKa|

Please login or register for full access


Already registered?  Login

Chat with BeiGene